In the news release, Halozyme To Host Third Quarter 2015
Financial Results Conference Call, issued 19-Oct-2015 by Halozyme Therapeutics, Inc. over
PR Newswire, we are advised by the company that the date of the
Quarterly Update Conference Call webcast should be "Monday, November 9 at 4:30
p.m. ET/1:30 p.m. PT" rather
than "Tuesday, November 10 at
4:30 p.m. ET/1:30 p.m. PT" as originally issued. The complete,
corrected release follows:
Halozyme To Host Third Quarter 2015 Financial Results Conference
Call
SAN DIEGO, Oct. 19, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the third quarter 2015 on Monday, November 9 at 4:30
p.m. ET/1:30 p.m. PT. Dr.
Helen Torley, president and chief
executive officer, will lead the call. On the same date
post-market, Halozyme will release financial results for the third
quarter 2015.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the call. To access the webcast and additional documents
related to the call, please visit www.halozyme.com approximately
fifteen minutes prior to the call to register, download and install
any necessary audio software. The live call may be accessed by
calling (877) 410-5657 (domestic callers) or (334) 323-7224
(international callers) using passcode 769890. A telephone replay
will be available after the call by dialing (877) 919-4059
(domestic callers) or (334) 323-0140 (international callers) using
replay ID number 75162222.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, metastatic breast
cancer and has potential across additional cancers in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug
delivery platform, ENHANZE™, which enables biologics and small
molecule compounds that are currently administered intravenously to
be delivered subcutaneously. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Contact:
Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-host-third-quarter-2015-financial-results-conference-call-300162219.html
SOURCE Halozyme Therapeutics, Inc.